α-Mangostin suppresses 12-o-tetradecanoylphorbol-13- acetate-mediated matrix metalloproteinase-9 expression in human osteosarcoma cells U2OS
Purpose: To investigate the effect of α-mangostin on matrix metalloproteinase (MMP)-2 and MMP-9 expression in U2OS human osteosarcoma cell lines.
Methods: Cytotoxicity of α-mangostin on U2OS cells was determined by MTT assay. MMP-2 and MMP- 9 activities, and mRNA expression of α-mangostin-treated U2OS cells were evaluated using gelatin zymography and real-time polymerase chain reaction (PCR), respectively. Wound healing assay was used to determine whether α-mangostin inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced migration of U2OS cells.
Results: U2OS viability was significantly decreased when cells were exposed to α-mangostin at 2.5 and 5 μg/mL compared to the untreated control (p < 0.05). α-Mangostin inhibited MMP-2 and MMP-9 activities stimulated by TPA at concentrations of 1.0, 1.5, and 2.0 μg/mL. MMP-9 mRNA expression of TPA treated U2OS was down-regulated by α-mangostin. However, MMP-2 mRNA levels remained unchanged. Would healing assay revealed that α-mangostin (2 μg/mL) significantly inhibited TPAinduced U2OS migration compared to the control (p < 0.05).
Conclusion: This is the first study reporting the inhibitory effects of α-mangostin on TPA-mediated MMP-9 expression and TPA-induced migration of U2OS cells. Thus, it is a potential therapeutic agent for the treatment of osteosarcoma.
Keywords: α-Mangostin, Matrix metalloproteinase, Osteosarcoma, Cell migration, 12-OTetradecanoylphorbol- 13-acetate, Wound healing, Zymography
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.